JP2012509846A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509846A5
JP2012509846A5 JP2011532298A JP2011532298A JP2012509846A5 JP 2012509846 A5 JP2012509846 A5 JP 2012509846A5 JP 2011532298 A JP2011532298 A JP 2011532298A JP 2011532298 A JP2011532298 A JP 2011532298A JP 2012509846 A5 JP2012509846 A5 JP 2012509846A5
Authority
JP
Japan
Prior art keywords
substituted
pharmaceutical composition
group
amino acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011532298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509846A (ja
JP5706825B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/061068 external-priority patent/WO2010045599A1/en
Publication of JP2012509846A publication Critical patent/JP2012509846A/ja
Publication of JP2012509846A5 publication Critical patent/JP2012509846A5/ja
Application granted granted Critical
Publication of JP5706825B2 publication Critical patent/JP5706825B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011532298A 2008-10-17 2009-10-16 フェノール性オピオイドの放出が減弱された医薬組成物 Active JP5706825B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10640008P 2008-10-17 2008-10-17
US61/106,400 2008-10-17
PCT/US2009/061068 WO2010045599A1 (en) 2008-10-17 2009-10-16 Pharmaceutical compositions with attenuated release of phenolic opioids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015037724A Division JP2015129167A (ja) 2008-10-17 2015-02-27 フェノール性オピオイドの放出が減弱された医薬組成物

Publications (3)

Publication Number Publication Date
JP2012509846A JP2012509846A (ja) 2012-04-26
JP2012509846A5 true JP2012509846A5 (enExample) 2012-12-06
JP5706825B2 JP5706825B2 (ja) 2015-04-22

Family

ID=41466912

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011532298A Active JP5706825B2 (ja) 2008-10-17 2009-10-16 フェノール性オピオイドの放出が減弱された医薬組成物
JP2015037724A Pending JP2015129167A (ja) 2008-10-17 2015-02-27 フェノール性オピオイドの放出が減弱された医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015037724A Pending JP2015129167A (ja) 2008-10-17 2015-02-27 フェノール性オピオイドの放出が減弱された医薬組成物

Country Status (12)

Country Link
US (2) US8802681B2 (enExample)
EP (1) EP2349241B1 (enExample)
JP (2) JP5706825B2 (enExample)
KR (1) KR20110081852A (enExample)
CN (1) CN102186467B (enExample)
AU (1) AU2009305563C1 (enExample)
CA (1) CA2739936C (enExample)
IL (1) IL212081A (enExample)
MX (1) MX2011004095A (enExample)
RU (1) RU2562583C2 (enExample)
WO (1) WO2010045599A1 (enExample)
ZA (1) ZA201102361B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2739936C (en) 2008-10-17 2017-12-12 Pharmacofore, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
WO2011008636A1 (en) * 2009-07-15 2011-01-20 Mallinckrodt Inc. 3-oxy-hydromorphone derivatives
US9493477B2 (en) * 2009-09-08 2016-11-15 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
US20110262359A1 (en) * 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
US9238020B2 (en) 2010-04-21 2016-01-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
CA2795222A1 (en) * 2010-04-21 2011-10-27 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
WO2011133348A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
WO2011133151A1 (en) * 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable phenol-modified opioid prodrugs and inhibitors thereof
US8497237B2 (en) 2011-01-11 2013-07-30 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
WO2012096887A2 (en) * 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
WO2012122420A2 (en) * 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
AU2012225337B2 (en) * 2011-03-09 2016-04-28 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
GB2545368B (en) 2014-10-20 2021-04-21 Elysium Therapeutics Inc Diversion-resistant opioid formulations
US11634384B2 (en) 2014-11-25 2023-04-25 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
GB2556817B (en) * 2015-10-01 2019-11-06 Elysium Therapeutics Inc Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) * 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
US10821105B2 (en) 2016-05-25 2020-11-03 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
AU2018234911B2 (en) 2017-03-17 2024-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
CA3107433A1 (en) 2018-07-27 2020-01-30 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic trpv1 agonists
WO2020181000A1 (en) 2019-03-06 2020-09-10 Ensysce Biosciences, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
MX2023010506A (es) 2021-03-09 2023-09-20 Ensysce Biosciences Inc Composiciones que comprenden profarmacos de escision enzimatica y nafamostat de liberacion controlada y metodos de uso de estos.
CA3230025A1 (en) 2021-09-29 2023-04-06 Lynn Kirkpatrick Enzyme-cleavable methadone prodrugs and methods of use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
US5109118A (en) * 1989-07-06 1992-04-28 Yutaka Mizushima Modified biologically active proteins
CA2032420A1 (en) 1989-12-22 1991-06-23 Akira Okuyama Guanidinobenzene derivatives
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
RU2166512C2 (ru) * 1995-01-16 2001-05-10 Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн Конъюгаты терапевтического соединения с жирной кислотой
WO1997037969A1 (en) 1996-04-10 1997-10-16 Ono Pharmaceutical Co., Ltd. Tryptase inhibitor and novel guanidino derivatives
CA2353872C (en) 1998-12-15 2011-05-03 Applied Biosystems, Llc Multiple enzyme assays
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
ATE267586T1 (de) 1999-02-18 2004-06-15 Supergen Inc An phosphocholin gebundene prodrug-derivate
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6897034B2 (en) 2001-06-11 2005-05-24 Medarex, Inc. CD10-activated prodrug compounds
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US20100092562A1 (en) 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
KR101159477B1 (ko) 2003-05-29 2012-07-02 샤이어 엘엘씨 남용 방지성 암페타민 화합물
WO2007022535A2 (en) * 2005-08-19 2007-02-22 Pharmacofore, Inc. Prodrugs of active agents
WO2007025286A2 (en) * 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
US7598273B2 (en) 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
EP1959948B1 (en) 2005-12-05 2012-07-18 XenoPort, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
WO2007120864A2 (en) 2006-04-14 2007-10-25 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
JP5371746B2 (ja) * 2006-05-26 2013-12-18 ファーマコフォア， インコーポレイテッド フェノール性オピオイドの制御放出
TWI401237B (zh) 2006-07-24 2013-07-11 ３-〔（１ｒ，２ｒ）-３-（二甲基氨基）-１-乙基-２-甲基丙基〕酚之製備
US20110105381A2 (en) 2007-02-16 2011-05-05 Pharmacofore, Inc. Prodrugs of Peripheral Phenolic Opioid Antagonists
US20120142718A1 (en) 2007-02-16 2012-06-07 Jenkins Thomas E N-17-Alkylated Prodrugs of Opioids
EP2219633A2 (en) 2007-11-23 2010-08-25 Nectid, Inc. Tapentadol compositions
US9023860B2 (en) 2007-11-26 2015-05-05 Signature Therapeutics, Inc. Pro-drugs for controlled release of biologically active compounds
WO2009092071A2 (en) 2008-01-18 2009-07-23 Shire Llc Amino acid and peptide pro-drugs of phenolic analgesics and uses thereof
EP2252150B1 (en) 2008-02-14 2018-04-11 Alkermes, Inc. Selective opioid compounds
CA2739936C (en) 2008-10-17 2017-12-12 Pharmacofore, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
US20100227921A1 (en) 2009-03-03 2010-09-09 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
KR20110134510A (ko) 2009-04-02 2011-12-14 샤이어 엘엘씨 오피오이드의 신규한 디카르복실산 연결 아미노산 및 펩티드 프로드러그와 그 용도
WO2011007247A1 (en) 2009-07-17 2011-01-20 Llc Shire Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
US20130079364A1 (en) 2010-04-21 2013-03-28 Signature Therapeutics, Inc. Peripheral Opioid Agonists and Peripheral Opioid Antagonists

Similar Documents

Publication Publication Date Title
US11859014B2 (en) Peptidomimetics for the treatment of Norovirus infection
US11629125B2 (en) Elimination of hepatitis b virus with antiviral agents
JP6153495B2 (ja) Ｃ型肝炎ウイルスの大環状阻害剤
JP2009538348A5 (enExample)
RU2011119643A (ru) Фармацевтические композиции с уменьшенным высвобождением фенольных опиоидов
JP7337833B2 (ja) 縮合二環式Ｃ５ａＲアンタゴニストのプロドラッグ
RU2012108874A (ru) Композиции, содержащие расщепляемые ферментами опиоидные пролекарства с модифицированным кетоном и их дополнительные ингибиторы
JP2007535491A5 (enExample)
JP2007534636A5 (enExample)
JP2013503862A5 (enExample)
AU707144B2 (en) Acylated N-hydroxymethyl thalidomide prodrugs having an immunomodulatory effect
JP2010514768A5 (enExample)
JP2009504763A5 (enExample)
RU2012104993A (ru) Тритерпеновые производные лупеольного типа как противовирусные препараты
JP2012510502A5 (enExample)
JP2005502621A5 (enExample)
JP2009530398A5 (enExample)
JP2010090149A5 (enExample)
JP2008546770A5 (enExample)
JP2012502048A5 (enExample)
JP2014505723A5 (enExample)
JP2014519507A5 (enExample)
JP2019503356A5 (enExample)
ES2835851T3 (es) Compuesto de indol amida como inhibidor de necrosis
WO2006043655A1 (ja) 吸入用医薬組成物